{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:46:10Z","timestamp":1794336370905,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>A retrospective and multicenter study was conducted on 100 SSA-resistant acromegaly patients and treated with Pasireotide Lar (Pasi-Lar), Peg-V in monotherapy (m-Peg-V) or in combination with first gen-SSA (c-Peg-V).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-three patients (33%) were treated with m-Peg-V, 36 (36%) with c-Peg-V and 31 with Pasi-Lar (31%). According to logistic regression, m-Peg-V was chosen in older patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) and with not-invasive adenomas (<jats:italic>p<\/jats:italic>\u2009=\u20090.009), c-Peg-V therapy in younger patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), with invasive adenomas (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), Pasi-Lar was in invasive adenomas (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) and in patients partially responsive to first-gen SSA (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). At the last follow-up, 68 patients (68%) reached the acromegaly control: 22 with m-Peg-V (32.4%), 23 with c-Peg-V (33.8%) and 23 with Pasi-Lar (33.8%). Patients non-responsive to c-Peg-V had higher IGF-I levels (median 3.2 x ULN, IQR: 1.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and required higher Peg-V dosage (median 30\u2009mg\/daily IQR: 10, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) as compared to responsive patients (median IGF-I x ULN: 2.1 IQR: 1.4; median Peg-V dosage 20\u2009mg\/daily IQR: 10). All patients responsive to Pasi-Lar were partially responsive to first gen-SSAs (<jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data showed that c-Peg-V and Pasi-Lar are chosen for the treatment of invasive tumors. The partial response to first gen-SSA seems to be the main determinant for the choice of Pasi-Lar and positively predicts the treatment outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-022-03158-w","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T10:02:40Z","timestamp":1660989760000},"page":"343-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly"],"prefix":"10.1007","volume":"78","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lauretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Sbardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Samperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Appetecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"3158_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"I.M. Holdaway, M.J. Bollard, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89\u201395 (2008). https:\/\/doi.org\/10.1530\/EJE-08-0267","journal-title":"Eur. J. Endocrinol"},{"issue":"9","key":"3158_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2011","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanuela, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2011). https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat. Rev. Endocrinol"},{"key":"3158_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","volume":"20","author":"MR Gadelha","year":"2018","unstructured":"M.R. Gadelha, L.E. Wildemberg, M.D. Bronstein, F. Gatto, D. Ferone, Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20, 100\u2013108 (2018)","journal-title":"Pituitary"},{"issue":"2","key":"3158_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247\u2013271 (2011). https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr. Rev."},{"issue":"4","key":"3158_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M.D. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A.M. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A.P. Heaney, K.K.Y. Ho, A.G. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A.M. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S.L. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M.L. Vance, J. Wass, M.E. Wierman, K.C.J. Yuen, M.C. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u2013678 (2020). https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"3158_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"M. Fleseriu, B.M.K. Biller, P.U. Freda, M.R. Gadelha, A. Giustina, L. Katznelson, M.E. Molitch, S.L. Samson, C.J. Strasburger, A.J. van der Lely, S. Melmed, A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1), 1\u201313 (2021). https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"key":"3158_CR7","doi-asserted-by":"publisher","unstructured":"R. Cozzi, M.R. Ambrosio, R. Attanasio, A. Bozzao, L. De Marinis, E. De Menis, E. Guastamacchia, A. Lania, G. Lasio, F. Logoluso, P. Maffei, M. Poggi, V. Toscano, M. Zini, P. Chanson, L. Katznelson, Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocr. Metab. Immune Disord. Drug Targets 20(8), 1144\u20131155 (2020). https:\/\/doi.org\/10.2174\/1871530320666200129113328","DOI":"10.2174\/1871530320666200129113328"},{"key":"3158_CR8","doi-asserted-by":"publisher","unstructured":"S. Chiloiro, A. Bianchi, F. Doglietto, C. de Waure, A. Giampietro, A. Fusco, D. Iacovazzo, L. Tartaglione, F. Di Nardo, S. Chiloiro, A. Bianchi, F. Doglietto, C. de Waure, A. Giampietro, A. Fusco, D. Iacovazzo, L. Tartaglione, F. Di Nardo, F. Signorelli, L. Lauriola, C. Anile, G. Maira, L. De Marinis, Radically resected pituitary adenomas: Prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature. Pituitary 17(3), 267\u2013276 (2014). https:\/\/doi.org\/10.1007\/s11102-013-0500-6","DOI":"10.1007\/s11102-013-0500-6"},{"issue":"3","key":"3158_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jc.2018-01524","volume":"104","author":"A Muhammad","year":"2019","unstructured":"A. Muhammad, E.C. Coopmans, F. Gatto, S.E. Franck, J.A.M.J.L. Janssen, A.J. van der Lely, L.J. Hofland, S.J.C.M.M. Neggers, Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. J. Clin. Endocrinol. Metab. 104(3), 915\u2013924 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01524","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3158_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study. Eur. J. Endocrinol. 174(2), 241\u2013250 (2016). https:\/\/doi.org\/10.1530\/EJE-15-0832","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"3158_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1677\/ERC-07-0288","volume":"15","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, A.B. Grossman, Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr. Relat. Cancer 15(3), 701\u2013720 (2008). https:\/\/doi.org\/10.1677\/ERC-07-0288","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"3158_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707\u2013716 (2002). https:\/\/doi.org\/10.1530\/eje.0.1460707","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3158_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-9966-32-40","volume":"32","author":"A Bianchi","year":"2013","unstructured":"A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res. 32(1), 40 (2013). https:\/\/doi.org\/10.1186\/1756-9966-32-40","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"3158_CR14","doi-asserted-by":"publisher","unstructured":"P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171\u20131177 (2000). https:\/\/doi.org\/10.1056\/NEJM200004203421604","DOI":"10.1056\/NEJM200004203421604"},{"key":"3158_CR15","doi-asserted-by":"publisher","unstructured":"A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 24(358(9295)), 1754\u20131759 (2001). https:\/\/doi.org\/10.1016\/s0140-6736(01)06844-1","DOI":"10.1016\/s0140-6736(01)06844-1"},{"key":"3158_CR16","doi-asserted-by":"publisher","unstructured":"J. Feenstra, W.W. de Herder, S.M. ten Have, A.W. van den Beld, R.A. Feelders, J.A. Janssen, A.J. van der Lely, Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 13(365(9471)), 1644\u20131646 (2005). https:\/\/doi.org\/10.1016\/S0140-6736(05)63011-5","DOI":"10.1016\/S0140-6736(05)63011-5"},{"key":"3158_CR17","doi-asserted-by":"publisher","unstructured":"J.O. J\u00f8rgensen, U. Feldt-Rasmussen, J. Frystyk, J.W. Chen, L.\u00d8. Kristensen, C. Hagen, H. \u00d8rskov, Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90(10), 5627\u20135631 (2005). https:\/\/doi.org\/10.1210\/jc.2005-0531","DOI":"10.1210\/jc.2005-0531"},{"key":"3158_CR18","doi-asserted-by":"publisher","unstructured":"P.J. Trainer, S. Ezzat, G.A. D\u2019Souza, G. Layton, C.J. Strasburger, A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin. Endocrinol. (Oxf.) 71(4), 549\u2013557 (2009). https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03620.x","DOI":"10.1111\/j.1365-2265.2009.03620.x"},{"key":"3158_CR19","doi-asserted-by":"publisher","unstructured":"A.J. van der Lely, I. Bernabeu, J. Cap, P. Caron, A. Colao, J. Marek, S. Neggers, P. Birman, Coadministration of lanreotide Autogel and Pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol. 164(3), 325\u2013333 (2011). https:\/\/doi.org\/10.1530\/EJE-10-0867","DOI":"10.1530\/EJE-10-0867"},{"key":"3158_CR20","doi-asserted-by":"publisher","unstructured":"M. Filopanti, L. Olgiati, G. Mantovani, S. Corbetta, M. Arosio, V. Gasco, L. De Marinis, C. Martini, F. Bogazzi, S. Cannav\u00f2, A. Colao, D. Ferone, G. Arnaldi, F. Pigliaru, A. Peri, G. Angeletti, M.L. Jaffrain-Rea, A.G. Lania, A. Spada, Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J. Clin. Endocrinol. Metab. 97(2), E165\u2013E172 (2012). https:\/\/doi.org\/10.1210\/jc.2011-1769","DOI":"10.1210\/jc.2011-1769"},{"issue":"2","key":"3158_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"S. Chiloiro, A. Giampietro, F. Mirra, F. Donfrancesco, T. Tartaglione, P.P. Mattogno, F. Angelini, L. Liverana, M. Gessi, A. Carmelo, G. Rindi, A. Giustina, M. Fleseriu, A. Pontecorvi, L. De Marinis, A. Bianchi, Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184(2), 217\u2013229 (2021). https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"3158_CR22","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1210\/jc.2019-00825","volume":"104","author":"S Chiloiro","year":"2019","unstructured":"S. Chiloiro, C. Bima, T. Tartaglione, A. Giampietro, M. Gessi, L. Lauretti, C. Anile, C. Colosimo, G. Rindi, A. Pontecorvi, L. De Marinis, A. Bianchi, Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. J. Clin. Endocrinol. Metab. 104(11), 5478\u20135482 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00825","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3158_CR23","doi-asserted-by":"publisher","first-page":"725014","DOI":"10.3389\/fendo.2021.725014","volume":"12","author":"O Cooper","year":"2021","unstructured":"O. Cooper, V. Bonert, N.A. Liu, A.N. Mamelak, Treatment of aggressive pituitary adenoma: a case-based narrative review. Front. Endocrinol. 12, 725014 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.725014","journal-title":"Front. Endocrinol."},{"key":"3158_CR24","doi-asserted-by":"publisher","unstructured":"S. Barraud, P. Caron, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, R. Henocque, Y. Brault, T. Brue, P. Chanson, B. Delemer, S. Barraud, P. Caron, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, R. Henocque, Y. Brault, T. Brue, P. Chanson, B. Delemer. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients) Ann Endocrinol (Paris). 2021; 10;S0003-4266(21)00078-0. https:\/\/doi.org\/10.1016\/j.ando.2021.05.004","DOI":"10.1016\/j.ando.2021.05.004"},{"issue":"1","key":"3158_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12902-020-0545-2","volume":"20","author":"L Ma","year":"2020","unstructured":"L. Ma, D. Luo, T. Yang, S. Wu, M. Li, C. Chen, S. Zhou, L. Ma, Y. Wu, Y. Zhou, Y. Cui, Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: A meta-analysis of prospective studies. BMC Endocr. Disord. 20(1), 18 (2020). https:\/\/doi.org\/10.1186\/s12902-020-0545-2","journal-title":"BMC Endocr. Disord."},{"issue":"4","key":"3158_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"M. Fleseriu, D. F\u00fchrer-Sakel, A.J. van der Lely, L. De Marinis, T. Brue, J. van der Lans-Bussemaker, J. Hey-Hadavi, C. Camacho-Hubner, M.P. Wajnrajch, S.R. Valluri, A.A. Palladino, R. Gomez, R. Salvatori, More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur. J. Endocrinol. 185(4), 525\u2013538 (2021). https:\/\/doi.org\/10.1530\/EJE-21-0239","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3158_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","volume":"67","author":"H Yamaguchi","year":"2020","unstructured":"H. Yamaguchi, A. Shimatsu, A. Okayama, T. Sato, Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocr. J. 67(2), 201\u2013210 (2020). https:\/\/doi.org\/10.1507\/endocrj.EJ19-0266","journal-title":"Endocr. J."},{"issue":"4","key":"3158_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.20945\/2359-3997000000160","volume":"63","author":"NXG Basavilbaso","year":"2019","unstructured":"N.X.G. Basavilbaso, M.C. Ballarino, D. Bruera, O.D. Bruno, A.B. Chervin, K. Danilowicz, P. Fainstein-Day, S.G. Fidalgo, A. Frigeri, M. Glerean, R. Guelman, G. Isaac, D.A. Katz, P. Knoblovits, F. Librandi, M.L. Montes, M.S. Mallea-Gil, M. Manavela, P. Mereshian, D. Moncet, A. Pignatta, A. Rogozinsky, L.R. Sago, M. Servidio, M. Spezzi, G. Stalldecker, J. Tkatch, N.M. Vitale, M. Guitelman, Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Arch. Endocrinol. Metab. 63(4), 320\u2013327 (2019). https:\/\/doi.org\/10.20945\/2359-3997000000160","journal-title":"Arch. Endocrinol. Metab."},{"issue":"4","key":"3158_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.20945\/2359-3997000000159","volume":"63","author":"CL Boguszewski","year":"2019","unstructured":"C.L. Boguszewski, M.K.P. Huayllas, L. Vilar, L.A. Naves, A. Ribeiro-Oliveira Junior, B.S. Soares, M.A. Czepielewski, J. Abucham, S.R. Correa-Silva, M.D. Bronstein, R.S. Jallad, F.G. Duarte, N.R. Musolino, L. Kasuki, M.R. Gadelha, Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328\u2013336 (2019). https:\/\/doi.org\/10.20945\/2359-3997000000159","journal-title":"Arch. Endocrinol. Metab."},{"issue":"6","key":"3158_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"M. Buchfelder, A.J. van der Lely, B.M.K. Biller, S.M. Webb, T. Brue, C.J. Strasburger, E. Ghigo, C. Camacho-Hubner, K. Pan, J. Lavenberg, P. J\u00f6nsson, J.H. Hey-Hadavi, Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur. J. Endocrinol. 179(6), 419\u2013427 (2018). https:\/\/doi.org\/10.1530\/EJE-18-0616","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3158_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","volume":"19","author":"I Bernabeu","year":"2016","unstructured":"I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escol\u00e1, J.A. Garc\u00eda-Arn\u00e9s, M. Marazuela, P. Jonsson, N. Mir, M. Garc\u00eda Vargas, Spanish ACROSTUDY Group, Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2), 127\u2013137 (2016). https:\/\/doi.org\/10.1007\/s11102-015-0691-0","journal-title":"Pituitary"},{"key":"3158_CR32","doi-asserted-by":"publisher","first-page":"633944","DOI":"10.3389\/fendo.2021.633944","volume":"12","author":"P Witek","year":"2021","unstructured":"P. Witek, M. Bolanowski, K. Szamotulska, A. Wojciechowska-Lu\u017aniak, A. Jawiarczyk-Przyby\u0142owska, M. Ka\u0142u\u017cny, The Effect of 6 Months\u2019 Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Front Endocrinol. (Lausanne) 12, 633944 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.633944","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"2","key":"3158_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"A. Akirov, A. Gorshtein, I. Dotan, N.S. Khazen, Y. Pauker, M. Gershinsky, I. Shimon, Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74(2), 396\u2013403 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"issue":"2","key":"3158_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"I. Shimon, Z. Adnan, A. Gorshtein, L. Baraf, N. Saba Khazen, M. Gershinsky, Y. Pauker, A. Abid, M.J. Niven, C. Shechner, Y. Greenman, Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2), 448\u2013455 (2018). https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"key":"3158_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0096-8","volume":"16","author":"MD Bronstein","year":"2016","unstructured":"M.D. Bronstein, M. Fleseriu, S. Neggers, A. Colao, M. Sheppard, F. Gu, C.C. Shen, M. Gadelha, A.J. Farrall, K. Hermosillo Res\u00e9ndiz, M. Ruffin, Y. Chen, P. Freda; Pasireotide C2305 Study Group, Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr. Disord. 16, 16 (2016). https:\/\/doi.org\/10.1186\/s12902-016-0096-8","journal-title":"BMC Endocr. Disord."},{"issue":"4","key":"3158_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1530\/EJE-17-0996","volume":"178","author":"CJ Strasburger","year":"2018","unstructured":"C.J. Strasburger, A. Mattsson, P. Wilton, F. Aydin, J. Hey-Hadavi, B.M.K. Biller, Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist Pegvisomant. Eur. J. Endocrinol. 178(4), 321\u2013329 (2018). https:\/\/doi.org\/10.1530\/EJE-17-0996","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3158_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12020-020-02501","volume":"71","author":"E Kuhn","year":"2021","unstructured":"E. Kuhn, P. Caron, B. Delemer, I. Raingeard, H. Lefebvre, G. Raverot, C. Cortet-Rudelli, R. Desailloud, C. Geffroy, R. Henocque, Y. Brault, T. Brue, P. Chanson, Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine 71(1), 158\u2013167 (2021). https:\/\/doi.org\/10.1007\/s12020-020-02501","journal-title":"Endocrine"},{"key":"3158_CR38","doi-asserted-by":"publisher","unstructured":"M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Br\u00fcbach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, Investigators of German Pegvisomant Observational Study. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161(1), 27\u201335 (2009). https:\/\/doi.org\/10.1530\/EJE-08-0910","DOI":"10.1530\/EJE-08-0910"},{"key":"3158_CR39","doi-asserted-by":"publisher","unstructured":"M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Br\u00fcbach, G.K. Stalla, C.J. Strasburger, German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Eur. J. Endocrinol. 161(1), S3\u2013S10 (2009). https:\/\/doi.org\/10.1530\/eje-09-0350","DOI":"10.1530\/eje-09-0350"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03158-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T19:31:00Z","timestamp":1666294260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03158-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["3158"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03158-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"5 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}